Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single Arm, Open-Label, Multicenter, Registry Study of Revcovi (Elapegademase-lvlr) Treatment in ADA-SCID Patients Requiring Enzyme Replacement Therapy

NCT03878069 is registered in ClinicalTrials.gov with Chiesi Farmaceutici S.p.A. as lead sponsor.

NCT NCT03878069
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03878069 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single Arm, Open-Label, Multicenter, Registry Study of Revcovi (Elapegademase-lvlr) Treatment in ADA-SCID Patients Requiring Enzyme Replacement Therapy
Lead sponsor
Chiesi Farmaceutici S.p.A.
Phase
Observational
Overall status
Completed
Start date
September 30, 2019
Completion date
January 18, 2023
Enrollment
32 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

adenosine deaminase severe combined immunodeficiency